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Over 2800 clinical strains of the Bacteroides fragilis group 
were collected during a 5-year period from ten geographically 
separate sites and tested for their susceptibility to various anti- 
microbial agents using a broth microdilution method. Among 
the cephalosporins, ceftizoxime was the most active (13% re- 
sistance) and importantly exhibited relatively equal activity 
against both B. fragilis species and non-B, fragilis species. 
Cefotaxime exhibited similar activity with an overall resistance 
rate of 18%. Both ceftriaxone and cefoperazone were apprecia- 
bly less active cephalosporins especially against non-B, fragilis 
species. With regard to cephamycins, cefoxitin (MIC9o, 32 
~g/ml) was more active than cefotetan (MIC9o, >1256 ~,g/ml) 
and cefmetazole (MIC9o , 64 p,g/ml). Non-B. fragilis species 
were highly resistant to cefotetan and cefmetazole. Imipenem 
was highly active against all strains with the exception of four 
strains of B. fragilis. Ampicillin-sulbactam, amoxicillin-cla- 
vulanate, piperacillin-tazobactam, and cefoperazone-sulbactam 
were all highly active with resistance rates <2%. No resis- 
tance was detected to metronidazole, whereas 14% of isolates 
were resistant to clindamycin. When compared with other 
studies, these findings underscore the wide variability in sus- 
ceptibility patterns reported nationwide and the need to con- 
tinue monitoring these patterns to aid in choosing the most 
active compounds for therapy. 
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I N T R O D U C T I O N  
The importance of anaerobic bacteria in mixed aer- 
obic-anaerobic infections is well established (Fine- 
gold and George, 1989). Members of the Bacteroides 
fragilis group are the most important and most fre- 
quently isolated anaerobes from human infections. 
Of the various species within the B. fragilis group, 
the B. fragilis species is the most commonly isolated 
and tends to be the most susceptible to a variety of 
antimicrobial agents, especially ~-lactams (Aldridge 
et al., 1984; Tally et al., 1985). It must be empha- 
sized, however,  that members of the non-B, fragilis 
species (B. distasonis, B. ovatus, B. thetaiotaomicron, 
and B. vulgatus) can comprise from 35% to 45% of 
the clinical isolates of the B. fragilis group (Brook, 
1988; Cuchural et al., 1988). Furthermore, strains of 
the non-B, fragilis species tend to be highly resistant 
to certain antibiotics, especially [~-lactams (Aldridge 
et al., 1988; Aldridge and Sanders, 1987; Goldstein 
and Citron, 1988). We performed a 5-year, multi- 
center study of the in vitro susceptibility of clinical 
isolates of the B. fragilis group. This report details 
the results of that s tudy from 1987 to 1991. Some of 
our results contrast with those of other recent mul- 
ticenter studies. 
MATERIALS AND METHODS 
Organisms 
Over a 5-year period, clinical isolates of the B. fragilis 
group were collected from ten medical centers 
within the United States and sent to a single refer- 
ence laboratory (Louisiana State University in New 
Orleans) for susceptibility testing. A total of 2876 
strains were tested, comprised of 1681 B. fragilis, 484 
B. thetaiotaomicron, 329 B. ovatus, 181 B. distasonis, 
165 B. vulgatus, 25 B. uniformis, 10 B. caccae, and 1 B. 
eggerthi. All isolates were identified by using selec- 
tive media, biochemical profiles, and gas-liquid 
chromatography (Jousimies-Somer and Finegold, 
1991; Holdeman et al., 1977; Summanen et al., 
1993). The sources of these isolates included ab- 
scesses, tissue, blood, body fluids, wounds,  gastro- 
intestinal and respiratory specimens, and bone. Be- 
cause of changes in the antimicrobial composition in 
the test panels during the 5 years, not all strains 
were tested against each antimicrobial agent. 
Antimicrobial Agents 
Laboratory standard powders  of each of the follow- 
ing agents were provided by the manufacturer: ce- 
foperazone, ampicillin, and sulbactam (Roerig Phar- 
maceuticals, New York City, NY, USA); ceftizoxime 
(Fujisawa Pharmaceuticals, Deerfield, IL, USA); 
amoxicillin and clavulanate (SmithKline Beecham 
Pharmaceuticals, Philadelphia, PA, USA); cefoxitin 
and imipenem (Merck Sharp and Dohme, West 
Point, PA, USA); cefotetan (Stuart Pharmaceuticals, 
Wilmington, DE, USA); piperacillin and tazobactam 
(Lederle Laboratories, Wayne, NJ, USA); cefotaxime 
(Hoechst-Roussel Pharmaceuticals, Somerville, NJ, 
USA); mezlocillin (Miles Pharmaceuticals, West Ha- 
ven, CT, USA); ceftriaxone (Roche Laboratories, 
Nutley, NJ, USA); clindamycin (Upjohn, Kalama- 
zoo, MI, USA); and metronidazole (G.D. Searle, 
Chicago, IL, USA). All standard powders  were 
stored desiccated at -20°C until use. 
Antimicrobial Susceptibility Testing 
Each strain was tested by a broth microdilution 
method as recommended by the National Commit- 
tee for Clinical Laboratory Standards (NCCLS, 
1988). Serial twofold dilutions of each antimicrobial 
agent (or combination) were prepared using anaer- 
obe broth MIC (Difco) within a dilution scheme of 
0.01 to 256 tzg/ml. When combining ampicillin or 
cefoperazone with sulbactam, or amoxicillin with 
clavulanate, a 2:1 ratio was used. Piperacillin was 
combined with tazobactam in an 8:1 ratio or a con- 
stant tazobactam concentration of 4 b~g/ml. The in- 
oculum of each strain was prepared by inoculating 
3-5 colonies into 5 ml of pre-reduced anaerobe broth 
MIC and incubating for 3-6 h anaerobically at 35°C. 
The broth culture was then adjusted to a density 
equal to a no. 1 McFarland nephelometer standard 
and further diluted to give a final inoculum size of 1 
x 105 colony forming units per well (1 x 10 6 CFU/ 
ml). All plates were incubated for 48 h at 35°C anaer- 
obically and then read. The MIC (minimum inhibi- 
tory concentration) was def ined as the lowest  
concentration of each antimicrobial agent (or com- 
bination) that inhibited the visible growth of the test 
isolate. If trailing end points were observed, the an- 
timicrobial concentration where the most significant 
reduction of growth was observed was chosen as 
the MIC. With each susceptibility run, quality assur- 
ance was performed with B. fragilis American Type 
Culture Collection (ATCC) 25285, B. thetaiotaomicron 
ATCC 29741, and Eubacterium lentum ATCC 43055. 
~-Lactamase Assay 
Production of ~-lactamase was detected by using a 
nitrocephin test (Cefinase; BBL, Cockeysville, MD, 
USA). 
RESULTS 
Table 1 compares the in vitro activity of the various 
antimicrobial agents against the B. fragilis group. 
Ceftizoxime was the most active cephalosporin with 
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TABLE 1 Comparison of in vitro Activity of Various Antimicrobials Against 
the Bacteroides fragilis Group 
No. of 
Strains Mode % 
Antimicrobial Tested Range a MIC MICso MIC9o Resistant b 
Ceftizoxime 2869 0.03-i>256 a
Cefotaxime 2868 0.06-~256 
Cefoperazone 2734 0.06-~256 
Ceftriaxone 1085 0.25-I>256 
Cefoxitin 2868 0.06-~>256 
Cefotetan 2869 0.06-~256 
Cefmetazole 742 0.06-~>256 
Piperacillin 2869 0.12-I>256 
Mezlocillin 1743 0.5--/>256 
Imipenem 2371 0.01-32 
Ampicillin-sulbactam 2391 0.03-/>256 
Amoxicillin- 
clavulanate 1649 0.06-64 
Cefoperazone- 
sulbactam 2390 0.01-/>256 
Piperacillin- 
tazobactam 1649 0.06-/>256 
Clindamycin 2869 0.01-I>256 
Metronidazole 2869 0.01-16 
2 4 64 13 
4 8 />256 18 
16 32 />256 34 
2 8 />256 34 
8 16 32 6 
8 8 />256 27 
8 16 64 20 
2 8 128 12 
8 8 128 12 
0.03 0.12 0.25 0.1 
1 1 4 1 
0.5 0.5 2 1.4 
2 4 16 0.7 
1 2 16 0.2 
0.5 0.5 8 14 
1 1 2 0 
aResults in izg/ml. 
bBased on NCCLS (1992) or manufacturer recommendations, the following MICs (~,g/ml) were 
used as the resistant cutoff values: ~8, clindamycin and amoxicillin-clavulanate; ~>16, imipenem; 
>~32, metronidazole and ampicillin-sulbactam; ~>64, ceftizoxirae, cefotaxime, cefoperazone, ceftri- 
axone, cefoxitin, cefotetan, cefmetazole, and cefoperazone-sulbactam; and 1>128, mezlocillin, 
piperacillin, and piperacillin-tazobactam. 
only 13% of the isolates being resistant and was fol- 
lowed by cefotaxime, cefoperazone, and ceftriaxone 
with resistance rates of 18%, 34%, and 34%, respec- 
tively. Among the cephamycins, resistance to cefox- 
itin was 6% compared with 27% and 20% to ce- 
fotetan and cefmetazole, respectively. Imipenem 
was the most active [3-1actam agent tested, with an 
MICgo of 0.25 ~g/ml and a resistance rate of 0.1%. 
Both piperacillin and mezlocillin showed compara- 
ble activity, with a 12% resistance rate for each. The 
addition of a [3-1actamase inhibitor to selected [3-1ac- 
tams appreciably enhanced the activity of the latter 
compounds.  A comparison of MICg0 of the ~-lac- 
tam-~-lactamase inhibitor combinations indicated 
that amoxicillin-clavulanate was only slightly more 
active than  ampic i l l in-su lbac tam but  eightfold 
more  active than ce fope razone - su lbac t am and 
piperaci l l in-tazobactam. Resistance rates to the 
c o m b i n a t i o n s  w e r e  low,  w i t h  p i p e r a c i l l i n -  
tazobactam having the lowest resistant rate (0.2%). 
Resistance to cl indamycin among the B. fragilis 
group was 14%, whereas no metronidazole resis- 
tance was detected. 
Table 2 compares the resistance rates of the B. 
fragilis group by test year. In general, increases in 
resistance over the 5 years were noted for the ceph- 
alosporins and cephamycins. Among the cephalo- 
sporins, cefoperazone resistance increased the most 
from 28% in 1987 to 41% in 1991. Both ceftizoxime 
and cefotaxime had a 5% variation in resistance 
rates during the testing years while ceftriaxone re- 
sistance remained in the low to middle 30 percent- 
ages during the same period. Among cephamycins, 
cefotetan showed a variation in resistance rates from 
22% to 31%. Cefmetazole was tested only during 
1989 and the resistance rate was 20% among those 
isolates. Cefoxitin resistance remained <10% for 
each test year. Resistance rates to piperacillin and 
mezlocillin were similar for all years tested, but 
overall piperacillin resistance increased slightly 
more among the isolates than did resistance to 
mezlocillin. For imipenem and the [3-1actam-~- 
lactamase inhibitor combinations, no consistent in- 
crease in resistance rates were observed. However,  
the resistance rates to clindamycin increased almost 
fourfold (5%-18%) during the 5-year period. 
Table 3 compares the resistance rates of the var- 
ious species of the B. fragilis group to the test anti- 
microbials. Among the cephalosporins, ceffizoxime 
was the most active against the various species. In 
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TABLE 2 Comparison of Resistance Rates (%) of 
the Bacteroides fragilis Group by 
Test Years 
Test Year 
Antimicrobial 1987 1988 1989 1990 1991 
Ceftizoxime 11 10 12 15 15 
Cefotaxime 15 16 18 20 19 
Cefoperazone 28 35 27 38 41 
Ceftriaxone 32 35 NIY 36 ND 
Cefoxitin 8 5 5 6 8 
Cefotetan 22 27 23 28 31 
Cefmetazole ND ND 20 ND ND 
Piperacillin 7 11 10 16 13 
Mezlocillin 11 10 ND 16 11 
Imipenem 0.1 0.2 0.2 ND 0 
Ampicillin- 
sulbactam ND 0.6 1.1 1.4 0.8 
Amoxicillin- 
clavulanate ND 1.8 ND 0.8 1.5 
Cefoperazone- 
sulbactam ND 1 2.7 5.8 1.2 
Piperacillin- 
tazobactam ND 0 ND 0.4 0.2 
Clindamycin 5 11 13 19 18 
Metronidazole 0 0 0 0 0 
~Not done. 
contrast, resistance rates to cefoperazone and ceftri- 
axone were very high among the non-B, fragilis spe- 
cies. Among the cephamycins, resistance rates to 
cefotetan and cefmetazole were high among B. the- 
taiotaomicron, B. ovatus, and B. distasonis. Cefoxitin 
was the most active cephamycin, but increased re- 
sistance was noted among the non-B, fragilis species 
compared with the B. fragilis species. Resistance 
rates to piperacillin and mezlocillin were similar 
among the various species; however, resistance 
rates were higher among non-B, fragilis species. 
Only a few strains of B. fragilis exhibited resistance 
to imipenem. Resistance to all [3-1actam/[3-1actamase 
inhibitor combinations was noted, but the highest 
rates were noted among B. distasonis and B. ovatus. 
Strains of non-B, fragilis species were appreciably 
more resistant to clindamycin than were B. fragilis 
strains. 
D I S C U S S I O N  
The resistance rates of the B. fragilis group to various 
antimicrobial agents have been reported to be both 
species and geographically dependent (Aldridge et 
al., 1984; Aldridge et al., 1988; Tally et al., 1985). The 
predominant mechanism of resistance to O-lactams 
among the B. fragilis group is [3-1actamase produc- 
tion (Nord et al., 1985). Although the most common 
[3-1actamases from these isolates are characterized as 
cephalosporinases, some B. fragilis group strains 
elaborate ~-lactamases capable of destroying antimi- 
crobials considered [3-1actamase stable such as cefox- 
itin, imipenem, and piperacillin (Cuchural et al., 
1983; Sato et al., 1982). Moreover, ~-lactamase- 
mediated cefoxitin resistance among strains of the 
B. fragilis group has been shown to be transferable 
(Cuchural et al., 1986a). 
Results of the present study confirm that there 
are significant differences in the activity of certain 
antimicrobial agents against B. fragilis group iso- 
lates. Among the single agents tested, metronida- 
zole and imipenem were the most active. Among 
the cephalosporin compounds,  ceftizoxime was 
more active than cefotaxime, cefoperazone, and cef- 
triaxone, while among cephamycins, cefoxitin was 
more active than cefotetan and cefmetazole. Piper- 
acillin, mezlocillin, and clindamycin had compara- 
ble resistance rates. With the exception of imi- 
penem, the non-B, fragilis species were significantly 
more resistant to the [3-1actam antimicrobials alone 
(no [3-1actamase inhibitor) than were strains of the B. 
fragilis species; a similar pattern was seen with clin- 
damycin. 
Prevention of ~-lactam degradation by addition 
of a [3-1actamase inhibitor has proven to be very ef- 
fective. The addition of sulbactam, clavulanate, or 
tazobactam significantly reduced the resistance 
rates to the accompanying ~-lactams and potenti- 
ated the activity of the antimicrobials by reducing 
the mode MICs and MICgo up to 32-fold and 64-fold, 
respectively. One strain of B. fragilis resistant to all 
of the [3-1actam-[3-1actamase inhibitor combinations 
except piperacillin-tazobactam was also resistant to 
all other [3-1actams tested. This strain probably pro- 
duces the metallo-containing [3-1actamase enzyme 
that has been shown to destroy all penicillins and 
cephalosporins (Cuchural et al., 1986b). 
A comparison of our data with the recent US re- 
ports by Cuchural et al. (1988 and 1990) shows sim- 
ilarities and differences. Overall, the two reports 
correlated well with regard to resistance rates to imi- 
penem, cefoxitin, piperacillin, cefoperazone, and 
clindamycin. However, reported resistance rates of 
22%, 23%, and 14% to ceftizoxime, cefotaxime, and 
cefotetan, respectively, differed from our results 
showing resistance rates of 13%, 18%, and 27% to 
the same antimicrobials. Furthermore, the ceftizox- 
ime MIC90 in our study was 64 ~g/ml compared with 
I>128 p,g/ml in their study. Our ceftizoxime data are 
in contrast to theirs and, from a comparison of our 
in vitro data, we can conclude that ceftizoxime has 
good coverage against B. fragilis group isolates with 
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TABLE 3 Comparison of Resistance Rates (%) of the Various Species of the 
Bacteroides fragilis Group to the Antimicrobials 
Bacteroides 
thetaiotao- 
Antimicrobial fragilis micron ovatus distasonis vulgatus Other ~ 
Ceftizoxime 11 16 15 17 8 11 
Cefotaxime 16 23 23 20 11 21 
Cefoperazone 25 51 57 31 25 12 
Ceftriaxone 19 72 58 46 31 31 
Cefoxitin 4 9 12 12 9 15 
Cefotetan 8 51 67 53 20 29 
Cefmetazole 0 0 0 0 0 33 
Piperacillin 9 13 16 17 18 9 
Mezlocillin 11 11 14 19 16 8 
Imipenem 0.2 0 0 0 0 0 
Ampicillin- 
sulbactam 0.7 0.5 1.4 5 0 0 
Amoxicillin- 
clavulanate 1.0 1.6 2.5 4.3 0 0 
Cefoperazone- 
sulbactam 1.8 2.7 3.1 0.7 1.4 0 
Piperacillin- 
tazobactam 0.1 0.4 0.4 0 0 0 
Clindamycin 8 20 26 22 18 13 
Metronidazole 0 0 0 0 0 0 
aContains 25 B. uniformis, 10 B. caccae, and 1 B. eggerthii. 
activity comparable to that of clindamycin. A clinical 
study by Bennion et al. (1992) in patients with per- 
forated or gangrenous appendicitis with peritonitis 
reported that  ceftizoxime exhibited good anti- 
anaerobic coverage. These differences in in vitro re- 
sults are probably related to differences in suscepti- 
bility testing methodologies (Aldridge and Sanders, 
1987; Aldridge et al., 1990). 
Other US investigators have reported the high 
level of activity with ~-lactam-f~-lactamase inhibitor 
combinations with results similar to ours. Barry et 
al. (1986) reported that sulbactam reduced the MIC90 
of ampicillin and cefoperazone from i>16 ~,g/ml to 2 
~g/ml and from 128 ~g/ml to 16 ~g/ml, respectively. 
Wexler et al. (1985) showed an MICgo reduction 
from ~256 ~g/ml to 8 ~g/ml when sulbactam was 
added to ampicillin. Clavulanate has been reported 
to increase the activity of amoxicillin 16-fold (Barry 
et al., 1986). Appelbaum et al. (1986) have also 
shown a significant increase in the activity of piper- 
acillin in the presence of tazobactam (YTR 830). In 
our study, ampicillin-sulbactam and amoxicillin- 
clavulanate appeared to be slightly more active 
(MICs) than the other ~-lactam-~-lactamase inhibi- 
tor combinations; however, no appreciable differ- 
ences in resistance rates were noted. Currently the 
approach of protecting ~-lactams with ~-lactamase 
inhibitors appears to remain highly effective. 
Phillips et al. (1992) reported on an in vitro survey 
of the susceptibility of B. fragilis group by using 
broth microdilution testing of isolates from 15 Euro- 
pean and Scandinavian countries. Their results 
were similar to ours with regard to amoxicillin- 
clavulanate, cefoxitin, cefotetan, imipenem, and 
metronidazole. Similarly we found imipenem resis- 
tance among B. fragilis strains. Notable differences 
for overall results were that mezlocillin resistance 
was 12% in our study versus 6% in theirs, and clin- 
damycin resistance was higher in our study (14% 
versus 9%). Our higher rates of clindamycin resis- 
tance more closely agree with reports from Spain 
and France (Dubreuil et al., 1992; Reig et al., 1984; 
Garcia-Rodriquez and Garcia-Sanchez, 1985). In Ja- 
pan, a report by Watanabe et al. (1992) described 
susceptibility patterns of B. fragilis and B. thetaio- 
taomicron strains. Resistance to imipenem was found 
among both groups of isolates, with resistance rates 
of 1.6% and 3.4%, respectively. They also reported 
good activity for ceftizoxime and cefoperazone- 
sulbactam similar to ours. For the two test groups, 
they reported clindamycin resistances of 24% and 
27.5%, respectively. Moreover, their piperacillin re- 
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sistance rate among  B. thetaiotaomicron was 26.8% 
compared  with our  13%. Fortunately  no met ronda-  
zole resistance was noted.  
This s tudy  has shown  that a variety of suscepti- 
bility pat terns  can be observed  among  strains of the 
B. fragilis group .  Cur r en t ly  me t ron idazo l e ,  imi- 
p e n e m ,  and  the  ~ - l ac tam-~- lac tamase  inh ib i tor  
combinat ions are the most  active. Good  activity was 
also seen for mezlocillin, piperacillin, ceftizoxime, 
cefoxitin, and cl indamycin.  Because of reports  of re- 
sistance to metronidazole ,  imipenem,  and other  an- 
timicrobials among  anaerobes  (Breuil et al., 1989; 
Brogan et al., 1989; LaMothe et al., 1986), addit ional 
in vitro studies to moni tor  changes in susceptibility 
pat terns  are war ran ted  not  only in the United States 
but  elsewhere.  
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